U.S. FDA Approves Tec-Dara for the Treatment of Relapsed/Refractory Multiple Myeloma Read more about U.S. FDA Approves Tec-Dara for the Treatment of Relapsed/Refractory Multiple Myeloma Add new comment
The International Myeloma Foundation Invites the Myeloma Community to Demonstrate the Spirit of #MoreThanMyeloma for 2026 Myeloma Action Month Read more about The International Myeloma Foundation Invites the Myeloma Community to Demonstrate the Spirit of #MoreThanMyeloma for 2026 Myeloma Action Month Add new comment
February 2026 – Myeloma News from the Journals Read more about February 2026 – Myeloma News from the JournalsAdd new comment
FDA Accepts New Drug Application for Iberdomide as Treatment for RRMM Read more about FDA Accepts New Drug Application for Iberdomide as Treatment for RRMM Add new comment
The International Myeloma Foundation Welcomes Dr. Stephen L. Houff to the IMF Board of Directors Read more about The International Myeloma Foundation Welcomes Dr. Stephen L. Houff to the IMF Board of DirectorsAdd new comment
FDA Grants Fast Track Designation for Trispecific Antibody IBI3003 as Treatment for Relapsed/Refractory Multiple Myeloma Read more about FDA Grants Fast Track Designation for Trispecific Antibody IBI3003 as Treatment for Relapsed/Refractory Multiple MyelomaAdd new comment
FDA Approves Darzalex Faspro in Combination with Bortezomib, Lenalidomide, and Dexamethasone (VRd) for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma Read more about FDA Approves Darzalex Faspro in Combination with Bortezomib, Lenalidomide, and Dexamethasone (VRd) for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma Add new comment
FDA Releases Draft Guidance for MRD and CR as Endpoints to Support Accelerated Approval for Myeloma Drugs Read more about FDA Releases Draft Guidance for MRD and CR as Endpoints to Support Accelerated Approval for Myeloma Drugs Add new comment
January 2026 – Myeloma News from the Journals Read more about January 2026 – Myeloma News from the JournalsAdd new comment
European Medicines Agency Receives Type II Variation Application from Johnson & Johnson for Tecvayli (teclistamab) in Combination with Subcutaneous Darzalex (daratumumab) for the Treatment of RRMM Read more about European Medicines Agency Receives Type II Variation Application from Johnson & Johnson for Tecvayli (teclistamab) in Combination with Subcutaneous Darzalex (daratumumab) for the Treatment of RRMMAdd new comment
